Caxton Corp raised its stake in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 12.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,820,012 shares of the specialty pharmaceutical company’s stock after acquiring an additional 196,445 shares during the quarter. Agile Therapeutics makes up 8.3% of Caxton Corp’s portfolio, making the stock its 3rd biggest holding. Caxton Corp owned approximately 5.32% of Agile Therapeutics worth $8,117,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AGRX. Royce & Associates LP increased its stake in Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock valued at $3,745,000 after purchasing an additional 11,000 shares during the last quarter. Royal Bank of Canada increased its stake in Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in Agile Therapeutics in the second quarter valued at $122,000. OxFORD Asset Management LLP acquired a new position in Agile Therapeutics in the third quarter valued at $161,000. Finally, Susquehanna International Group LLP acquired a new position in Agile Therapeutics in the second quarter valued at $205,000. 72.96% of the stock is owned by institutional investors.

Shares of Agile Therapeutics, Inc. (NASDAQ AGRX) opened at $4.56 on Thursday. Agile Therapeutics, Inc. has a 1 year low of $1.82 and a 1 year high of $7.06. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.03. equities analysts predict that Agile Therapeutics, Inc. will post -0.99 earnings per share for the current fiscal year.

Several equities analysts recently commented on AGRX shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $8.00 target price on shares of Agile Therapeutics in a research note on Monday, November 20th. Royal Bank Of Canada upped their target price on Agile Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Thursday, September 14th. HC Wainwright set a $10.00 target price on Agile Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. Janney Montgomery Scott reiterated a “buy” rating and issued a $13.00 target price on shares of Agile Therapeutics in a research note on Thursday, September 7th. Finally, ValuEngine lowered Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $10.20.

COPYRIGHT VIOLATION NOTICE: “Caxton Corp Has $8.12 Million Stake in Agile Therapeutics, Inc. (AGRX)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/07/caxton-corp-has-8-12-million-stake-in-agile-therapeutics-inc-agrx.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Institutional Ownership by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.